Global law firm Clyde & Co has today announced the appointment of Brian Greenwood and Stephen Webb as Partners to its highly regarded planning group in London, led by Partner Ian Ginbey, which will become one of the largest of its kind in the UK. More >>

International legal practice Osborne Clarke has hired Jakub Kubicki to bolster its London Banking practice. More >>

Global law firm Norton Rose Fulbright today announces that David Marshall has joined as a partner in London. More >>

Widely respected M&A and private equity lawyer Shaun Lascelles has joined Vinson & Elkins LLP as a partner, enhancing the firm’s growing Private Equity practice group in London. More >>

Bird & Bird is delighted to announce the appointment of Richard Vary as a partner in our international Intellectual Property and Tech & Comms Sector groups, based in London. More >>

Squire Patton Boggs has appointed Kashif Siddiqui as a partner in its Global Corporate Practice in London. More >>

International law firm Clifford Chance today announces that leading Intellectual Property (IP) practitioner, Stephen Reese, will join the firm’s London office as a partner on Monday 3 October 2016. More >>

Allen & Overy announces the appointments of Mark Heaney and David Stone to the international IP practice. Both join from Simmons & Simmons and build on the news that Marc Döring and Marjan Noor will also be joining the team. This four partner move demonstrates A&O’s commitment to the IP sector by doubling the size of the London partner group. More >>

Winston & Strawn LLP announced today that Matthew Bate has joined the firm as a partner in its International Arbitration Practice in London. Mr. Bate, who comes to Winston from Akin Gump Strauss Hauer & Feld LLP, advises and represents parties in relation to international commercial arbitrations, as well as investment treaty arbitrations. More >>

Eversheds has advised Horizon Pharma plc on the European aspects of its $800 million acquisition of Raptor Pharmaceutical corporation which strengthens Horizon’s focus on rare disease and bolsters their expansion into Europe and other international markets. More >>